Predicting Prognosis and Recurrence of Thyroid Cancer Via New Biomarkers, Urinary Exosomal Thyroglobulin and Galectin-3
CompletedOBSERVATIONAL
Enrollment
74
Participants
Timeline
Start Date
August 3, 2018
Primary Completion Date
July 31, 2023
Study Completion Date
February 20, 2024
Conditions
Thyroid Cancer
Trial Locations (1)
100-02
National Taiwan University Hospital, Taipei
All Listed Sponsors
lead
National Taiwan University Hospital
OTHER
NCT03488134 - Predicting Prognosis and Recurrence of Thyroid Cancer Via New Biomarkers, Urinary Exosomal Thyroglobulin and Galectin-3 | Biotech Hunter | Biotech Hunter